Detecting and Treating Clostridium Difficile Infections in Patients with Inflammatory Bowel Disease
Detecting and Treating Clostridium Difficile Infections in Patients with Inflammatory Bowel Disease
复制标题
DOI：
10.1016/j.gtc.2012.01.003
复制
发表时间：
2012-06-01
影响因子：
3.7
通讯作者：
Ananthakrishnan, Ashwin N.
中科院分区：
文献类型：
--
作者：
Ananthakrishnan, Ashwin N.
一个队列，似乎是在艰难梭菌感染（CDI）的风险较高，特别容易受到与它相关的发病率和死亡率是患者的基础炎症性肠病（IBD）。诊断需要从腹泻粪便样本中证明毒素。轻度CDI可口服甲硝唑治疗，而严重的疾病应口服万古霉素治疗。对经常性CDI的管理仍然具有挑战性。现在有了新的药物，这些药物似乎有效，而且疾病复发的风险较低。需要对IBD患者进行CDI的特定治疗试验和前瞻性研究。
A cohort that appears to be at a higher risk for Clostridium difficile infection (CDI) and particularly vulnerable to the morbidity and mortality associated with it are patients with underlying inflammatory bowel diseases (IBD). Diagnosis requires demonstration of the toxin from a diarrhea stool sample. Mild CDI can be treated with oral metronidazole, whereas severe disease should be treated with oral vancomycin. Management of recurrent CDI remains challenging. Newer drugs are now available that appear to be effective with lower risk of disease recurrence. Specific treatment trials and prospective studies of CDI in patients with IBD are warranted.